Cardiovascular disease seriously endangers human health, and its morbidity and mortality increase year by year, and the incidence population is gradually younger. Myocardial fibrosis is a common pathological outcome of many heart diseases, and it is of great clinical significance to prevent and reverse cardiac fibrosis. Under the influence of various pathogenic factors, the heart eventually leads to the formation of myocardial fibrosis, which in turn leads to heart failure. However, the specific mechanism of myocardial fibrosis formation is unknown. The transient receptor potential channel is closely related to the formation of myocardial fibrosis, and can be targeted to intervene in this channel to play an antifibrotic role. This review elaborates the role of transient receptor potential channels in the formation of myocardial fibrosis, which provides new ideas for clinical treatment and basic research.

Rong Fang, Yuanwang Yu. Research Progress on Transient Receptor Potential Channels and Myocardial Fibrosis. Frontiers in Medical Science Research (2024), Vol. 6, Issue 1: 49-54. https://doi.org/10.25236/FMSR.2024.060109.

[1] In China The Writing Committee Of The Report On Cardiovascular Health And Diseases, Hu ShengShou. Report on cardiovascular health and diseases in China 2021: an updated summary [J]. Journal of geriatric cardiology: JGC, 2023, 20(6):399-430. 

[2] Michelle D. Tallquist. Cardiac Fibroblast Diversity [J]. Annual Review of Physiology, 2020, 82(1):63-78. 

[3] Gwanyanya Asfree, Mubagwa Kanigula. Emerging role of transient receptor potential (TRP) ion channels in cardiac fibroblast pathophysiology [J]. Frontiers in Physiology, 2022, 13:968393-968393. 

[4] Cosens D J, Manning A. Abnormal electroretinogram from a Drosophila mutant [J]. Nature, 1969, 224(5216):285-287. 

[5] Ryuji Inoue, Lin-Hai Kurahara, Keizo Hiraishi, et al. TRP channels in cardiac and intestinal fibrosis [J]. Seminars in Cell and Developmental Biology, 2019, 94:40-49. 

[6] Yue Zhichao, Xie Jia, Yu Albert S, et al. Role of TRP channels in the cardiovascular system [J]. American journal of physiology. Heart and circulatory physiology, 2015, 308(3):H157-H182. 

[7] Alexander Dietrich. Transient Receptor Potential (TRP) Channels in Health and Disease [J]. Cells, 2019, 8(5):413- 413. 

[8] Monika Lodyga, Boris Hinz. TGF-β1 – A truly transforming growth factor in fibrosis and immunity [J]. Seminars in Cell and Developmental Biology, 2020, 101:123-139. 

[9] Meng Linlin, Lu Yue, Wang Xinlu, et al. NPRC deletion attenuates cardiac fibrosis in diabetic mice by activating PKA/PKG and inhibiting TGF-β1/Smad pathways [J]. Science advances, 2023, 9(31):eadd4222-eadd4222. 

[10] Garlapati Venkata, Molitor Michael, Michna Thomas, et al. Targeting myeloid cell coagulation signaling blocks MAP kinase/TGF-β1 driven fibrotic remodeling in ischemic heart failure [J]. The Journal of clinical investigation, 2022, 133(4):1-21. 

[11] Khalil Hadi, Kanisicak Onur, Prasad Vikram, et al. Fibroblast-specific TGF-β-Smad2/3 signaling underlies cardiac fibrosis [J]. The Journal of clinical investigation, 2017, 127(10):3770-3783. 

[12] Ahn Min-Soo, Eom Young Woo, Oh Ji-Eun, et al. Transient receptor potential channel TRPV4 mediates TGF-β1-induced differentiation of human ventricular fibroblasts [J]. Cardiology journal, 2020, 27(2):162-170.

[13] Rahaman Shaik O, Grove Lisa M, Paruchuri Sailaja, et al. TRPV4 mediates myofibroblast differentiation and pulmonary fibrosis in mice [J]. The Journal of clinical investigation, 2014, 124(12):5225-5238. 

[14] Okada Yuka, Shirai Kumi, Reinach Peter S, et al. TRPA1 is required for TGF-β signaling and its loss blocks inflammatory fibrosis in mouse corneal stroma [J]. Laboratory investigation; a journal of technical methods and pathology, 2014, 94(9):1030-1041. 

[15] Kurahara Lin Hai, Sumiyoshi Miho, Aoyagi Kunihiko, et al. Intestinal myofibroblast TRPC6 channel may contribute to stenotic fibrosis in Crohn's disease [J]. Inflammatory bowel diseases, 2015, 21(3):496-506. 

[16] Jianlin Feng, Maria K. Armillei, Albert S. Yu, et al. Ca2+ Signaling in Cardiac Fibroblasts and Fibrosis-Associated Heart Diseases [J]. Journal of Cardiovascular Development and Disease, 2019, 6(4):34-34. 

[17] Craig Montell, Lutz Birnbaumer, Veit Flockerzi, et al. The TRP Channels, a Remarkably Functional Family [J]. Cell, 2002, 108(5):595-598. 

[18] Harada Masahide, Luo Xiaobin, Qi Xiao Yan, et al. Transient receptor potential canonical-3 channel-dependent fibroblast regulation in atrial fibrillation [J]. Circulation, 2012, 126(17):2051-2064. 

[19] Nishida Motohiro, Onohara Naoya, Sato Yoji, et al. Gα12/13-mediated Up-regulation of TRPC6 Negatively Regulates Endothelin-1-induced Cardiac Myofibroblast Formation and Collagen Synthesis through Nuclear Factor of Activated T Cells Activation [J]. Journal of Biological Chemistry, 2007, 282(32):23117-23128. 

[20] Du Jianyang, Xie Jia, Zhang Zheng, et al. TRPM7-mediated Ca2+ signals confer fibrogenesis in human atrial fibrillation [J]. Circulation research, 2010, 106(5):992-1003. 

[21] Earley Scott, Brayden Joseph E. Transient receptor potential channels in the vasculature [J]. Physiological reviews, 2015, 95(2):645-690. 

[22] Talavera Karel, Startek Justyna B, Alvarez-Collazo Julio, et al. Mammalian Transient Receptor Potential TRPA1 Channels: From Structure to Disease [J]. Physiological reviews, 2020, 100(2):725-803.

[23] Oguri Gaku, Nakajima Toshiaki, Yamamoto Yumiko, et al. Effects of methylglyoxal on human cardiac fibroblast: roles of transient receptor potential ankyrin 1 (TRPA1) channels [J]. American journal of physiology. Heart and circulatory physiology, 2014, 307(9):H1339-H1352. 

[24] Li Shuang, Sun Xiongshan, Wu Hao, et al. TRPA1 Promotes Cardiac Myofibroblast Transdifferentiation after Myocardial Infarction Injury via the Calcineurin-NFAT-DYRK1A Signaling Pathway [J]. Oxidative Medicine and Cellular Longevity, 2019, 2019:6408352. 

[25] Andrei Spencer R, Sinharoy Pritam, Bratz Ian N, et al. TRPA1 is functionally co-expressed with TRPV1 in cardiac muscle: Co-localization at z-discs, costameres and intercalated discs [J]. Channels (Austin, Tex.), 2016, 10(5):395-409. 

[26] Nadezhdin Kirill D., Correia Leonor, Narangoda Chamali, et al. Structural mechanisms of TRPM7 activation and inhibition [J]. Nature Communications, 2023, 14(1):2639-2639. 

[27] Zhiguo Zou, Francisco J. Rios, Augusto C. Montezano, et al. TRPM7, Magnesium, and Signaling [J]. International Journal of Molecular Sciences, 2019, 20(8):1877-1877. 

[28] Rios Francisco J, Zou Zhi-Guo, Harvey Adam P, et al. Chanzyme TRPM7 protects against cardiovascular inflammation and fibrosis [J]. Cardiovascular research, 2020, 116(3):721-735. 

[29] Li Sha, Li Mingjiang, Yi Xin, et al. TRPM7 channels mediate the functional changes in cardiac fibroblasts induced by angiotensin II [J]. International journal of molecular medicine, 2017, 39(5):1291-1298. 

[30] Wei Yanchun, Wu Yan, Feng Kai, et al. Astragaloside IV inhibits cardiac fibrosis via miR-135a-TRPM7-TGF-β/Smads pathway [J]. Journal of Ethnopharmacology, 2020, 249:112404. 

[31] Tiapko Oleksandra, Groschner Klaus. TRPC3, an underestimated, universal pacemaker channel? [J]. Cell Calcium, 2021, 100:102484-102484. 

[32] Yue-Kun eJu, Bon Hyang Lee, Sofie eTrajanovska, et al. The Involvement of TRPC3 channels in Sinoatrial Arrhythmias [J]. Frontiers in Physiology, 2015, 6:86. 

[33] Hiroyuki Watanabe, Manabu Murakami, Takayoshi Ohba, et al. TRP channel and cardiovascular disease [J]. Pharmacology and Therapeutics, 2008, 118(3):337-351. 

[34] Kiyonaka Shigeki, Kato Kenta, Nishida Motohiro, et al. Selective and direct inhibition of TRPC3 channels underlies biological activities of a pyrazole compound [J]. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106(13):5400-5405.

[35] Chen Xingjuan, Sooch Gagandeep, Demaree Isaac S., et al. Transient Receptor Potential Canonical (TRPC) Channels: Then and Now [J]. Cells, 2020, 9(9):1983-1983. 

[36] Jennifer Davis, Adam R. Burr, Gregory F. Davis, et al. A TRPC6-Dependent Pathway for Myofibroblast Transdifferentiation and Wound Healing In Vivo [J]. Developmental Cell, 2012, 23(4):705-715. 

[37] Lin Brian Leei, Matera Damian, Doerner Julia F, et al. In vivo selective inhibition of TRPC6 by antagonist BI 749327 ameliorates fibrosis and dysfunction in cardiac and renal disease [J]. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116(20):10156-10161. 

[38] Chaigne Sébastien, Barbeau Solène, Ducret Thomas, et al. Pathophysiological Roles of the TRPV4 Channel in the Heart [J]. Cells, 2023, 12(12). 

[39] Adapala Ravi K, Kanugula Anantha K, Paruchuri Sailaja, et al. TRPV4 deletion protects heart from myocardial infarction-induced adverse remodeling via modulation of cardiac fibroblast differentiation [J]. Basic research in cardiology, 2020, 115(2):14.